GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Total Current Liabilities

Invex Therapeutics (ASX:IXC) Total Current Liabilities : A$0.48 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Invex Therapeutics's total current liabilities for the quarter that ended in Dec. 2024 was A$0.48

Invex Therapeutics Total Current Liabilities Historical Data

The historical data trend for Invex Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Total Current Liabilities Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Total Current Liabilities
2.02 0.66 1.00 1.57 0.43

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.16 1.57 0.99 0.43 0.48

Invex Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Invex Therapeutics's Total Current Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.432+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.43

Invex Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.48+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Invex Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Total Current Liabilities
Comparable Companies
ASX:CHM ASX:NSB ASX:ZLD ASX:BGT ASX:ACR ASX:PAB ASX:MEM ASX:1AI ASX:CMB ASX:BIT VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Website
https://www.invextherapeutics.com
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

Invex Therapeutics Headlines

From GuruFocus

Versant Capital Management, Inc Buys BTC iShares Global Energy ETF, Goldman Sachs BDC Inc, PowerShares QQQ Trust Ser 1, Sells The Home Depot Inc, Apple Inc, Invesco Emerging Markets Sovereign Debt ETF

By GuruFocus Research GuruFocus Editor • 02-08-2021

Sentinel Trust Co Lba Buys iShares Global Energy ETF, Tesla Inc, iShares MSCI USA ESG Optimized ETF, Sells Huntington Bancshares Inc, Exxon Mobil Corp, Chevron Corp

By GuruFocus Research GuruFocus Editor • 10-19-2021

Fisher Asset Management, LLC Buys ISHARES TRUST, iShares MSCI Europe Financial Sector Index Fund, Global Payments Inc, Sells Total SE, Royal Dutch Shell PLC, CoreLogic Inc

By GuruFocus Research GuruFocus Editor • 11-10-2020

Verger Capital Management LLC Buys iShares Global Energy ETF, iShares Gold Trust

By GuruFocus Research GuruFocus Editor • 10-29-2021

Newfound Research LLC Buys iShares Global Energy ETF, iShares Global Financials ETF, BorgWarner Inc, Sells iShares U.S. Preferred Stock, iShares iBoxx $ High Yield Corporate Bond ETF, iShares iBoxx $ Investment Grade Corporate Bond ET

By [email protected] insider • 02-10-2020

Verger Capital Management LLC Buys BTC iShares Global Energy ETF, BTC iShares U.S. Technology ETF, Sells iShares MSCI ACWI Index Fund, SSgA Financial Select Sector SPDR, SSGA SPDR S&P 500

By GuruFocus Research GuruFocus Editor • 02-19-2021

Versant Capital Management, Inc Buys iShares Global Energy ETF, Amazon.com Inc, Schwab Fundamental International Small Company Ind, Sells Eli Lilly and Co, iShares Gold Trust, Prudential Financial Inc

By GuruFocus Research GuruFocus Editor • 07-22-2021

Ken Fisher's Top 4th-Quarter Trades

By Graham Griffin Graham Griffin • 02-01-2021

Verger Capital Management LLC Buys iShares Global Energy ETF

By [email protected] insider • 11-04-2019

Alpha Cubed Investments, LLC Buys iShares Global Energy ETF, CVS Health Corp, Newmont Corp, Sells iShares MBS ETF, Vulcan Materials Co, Intuitive Surgical Inc

By GuruFocus Research GuruFocus Editor • 07-20-2021